UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026
Rhea-AI Summary
UroGen Pharma (Nasdaq: URGN) will report fourth quarter and full-year 2025 financial results on Monday, March 2, 2026, before the market opens. A live audio webcast and conference call will follow at 10:00 AM Eastern Time.
According to the company, the live public webcast will be accessible via its investor relations website, with a replay available on the site for approximately 30 days after the call.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
URGN is down 3.35% while close biotech peers show mixed moves: EYPT up 5.14%, SYRE up 14.25%, OCS up 2.53%, and SANA/QURE modestly negative. Momentum data flags only EYPT on the scanner and moving down there, reinforcing a stock-specific tone for URGN rather than a broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 04 | Conference appearance | Positive | +3.5% | Announced participation in Guggenheim biotech summit with webcast access. |
| Jan 05 | Reimbursement update | Positive | -2.5% | Permanent J Code J9282 for ZUSDURI became effective to ease reimbursement. |
| Dec 05 | Equity inducement grants | Neutral | -4.8% | RSU inducement grants to new employees under 2019 Inducement Plan. |
| Nov 25 | Conference appearance | Positive | +2.8% | Planned fireside chat at Piper Sandler healthcare conference with webcast. |
| Nov 06 | Earnings report | Positive | +21.9% | Q3 2025 earnings highlighting ZUSDURI launch traction and pipeline progress. |
Recent news has often seen positive or neutral corporate updates met with mostly aligned price reactions, with one notable divergence when reimbursement-related news coincided with a negative move.
Over the last few months, URGN has reported several milestones, including Q3 2025 earnings on Nov 6, 2025 with strong uptake of ZUSDURI and JELMYTO, which saw a 21.91% positive reaction. Subsequent conference appearances on Nov 25, 2025 and Feb 4, 2026 also drew modest gains. A reimbursement-focused J-code update on Jan 5, 2026 coincided with a -2.55% move, while inducement grants on Dec 5, 2025 were followed by a -4.81% decline. Today’s earnings-date notice fits into this cadence of scheduled corporate communications.
Market Pulse Summary
This announcement sets the timing for URGN’s fourth quarter and full-year 2025 results on March 2, 2026, with a conference call at 10:00 AM ET and a webcast replay for about 30 days. In light of prior earnings that showcased ZUSDURI and JELMYTO performance, investors may focus on revenue trends, operating losses, and cash levels. Historical news flow shows the stock can react meaningfully to earnings quality and commercial updates, underscoring the importance of the upcoming release.
AI-generated analysis. Not financial advice.
Conference Call and Webcast Scheduled for Monday, March 2, 2026 at 10:00 AM ET
PRINCETON, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report fourth quarter and full-year 2025 financial results on Monday, March 2nd , 2026, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time.
A live public webcast of the earnings conference call can be accessed on UroGen’s Investor Relations website. Following the live webcast, a replay will be available on the site for approximately 30 days.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first product is approved to treat low-grade upper tract urothelial cancer, and UroGen’s second product is the first and only FDA-approved medication for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Both medicines are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.UroGen.com to learn more or follow us on X (Twitter), @UroGenPharma.
INVESTOR CONTACT:
Vincent Perrone
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093
MEDIA CONTACT:
Cindy Romano
Director, Corporate Communications
cindy.romano@urogen.com
609-460-3583 ext. 1083
FAQ
When will UroGen (URGN) report Q4 and full-year 2025 results?
How can investors join the UroGen (URGN) earnings call on March 2, 2026?
Will a replay of the UroGen (URGN) March 2, 2026 earnings call be available?
What time is the UroGen (URGN) conference call for Q4 and full-year 2025 results?
Where can I find materials or slides for UroGen's (URGN) March 2, 2026 earnings presentation?
